FilingReader Intelligence
Zhejiang Medicine boosts 2024 profit, proposes cash dividend
April 23, 2025 at 05:38 PM UTC•By FilingReader AI
Zhejiang Medicine (SSE:600216) has announced a robust financial performance for 2024, accompanied by a proposal to distribute CNY355.8 million in cash dividends. The company's board has approved a plan to allocate CNY0.37 per share to all shareholders, contingent on shareholder approval at the upcoming 2024 Annual General Meeting.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Zhejiang Medicine: 2024 Annual Audit ReportApril 23, 2025 at 09:41 AM UTC
Zhejiang Medicine 2024 Annual Report SummaryApril 23, 2025 at 09:28 AM UTC
Zhejiang Medicine 2025 First Quarter ReportApril 23, 2025 at 09:28 AM UTC
Zhejiang Medicine: Special audit statement on non-operating capital occupation and other related capital transactions in 2024April 23, 2025 at 09:41 AM UTC
Zhejiang Medicine 2024 Internal Control Evaluation ReportApril 23, 2025 at 09:41 AM UTC
Zhejiang Medicine 2024 Annual Profit Distribution Plan AnnouncementApril 23, 2025 at 09:41 AM UTC
Zhejiang Medicine's announcement on reappointment of accounting firmApril 23, 2025 at 09:41 AM UTC
News Alerts
Get instant email alerts when Zhejiang Medicine publishes news
Free account required • Unsubscribe anytime